Optimal antipsychotic dosing in first-episode schizophrenia: how much is too little, too much, or just right?

towfiqu-barbhuiya-Yw9Vgr6i_-0-unsplash

Joe Pierre reports on the first published study exploring the relationship between antipsychotic dose and risk of relapse in first episode schizophrenia, which suggests that standard antipsychotic dosing is best for relapse prevention.

[read the full story...]

An INTREPID journey into the epidemiological landscape of psychosis in the Global South

jen-theodore-tWqyWrqLntU-unsplash

Shuichi Suetani and Jon Paul Teo discuss the International Research Program on Psychotic Disorders in Diverse Settings (INTREPID II) study, which investigates the epidemiology of untreated psychoses in 3 diverse settings in the Global South.

[read the full story...]

Antipsychotics for acute treatment of first episode schizophrenia

Creative-Tail-medicine.svg

Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.

[read the full story...]

Omega-3 fatty acids to prevent psychosis: the importance of replication (NEURAPRO trial)

22421169767_03c5cce9cf_z

Raphael Underwood summarises the NEURAPRO trial, which concludes that Omega-3 fatty acids are no better than placebo at preventing transition to psychosis in young people at ultrahigh risk for psychotic disorders.

[read the full story...]

Outcomes in first episode manic psychosis

photo-1423420634464-89006b3454a8

Matthew Broome writes his debut Mental Elf blog on a three-year clinical and functional outcome comparison between first episode manic psychosis and first-episode schizophrenia.

[read the full story...]

Prognosis of brief psychotic episodes

3917186281_bb24ceabb8_o

Samei Huda presents the findings of a new meta-analysis, which explores the prognostic significance of competing ways of defining and measuring brief psychotic episodes.

[read the full story...]